Slide 1: Investor Presentation February 17, 2010
Investor Presentation February 17, 2010
Slide 2: Forward-looking statements
This presentation includes forward-looking statements about: our strategy for maximizing shareholder value the ability to improve the benefit-risk profile of TYSABRI(r) and drive future growth ongoing development initiatives and growth strategies for our marketed products the anticipated development
Slide 3: 2009 in Review
2009 in Review TYSABRI achieved 'blockbuster' status Late stage MS pipeline advanced and expanded Revenue grew despite headwinds Operating margin reached nearly 40% $1 billion stock buyback initiated
Slide 4: Key Levers to Maximize Shareholder Value
13 Disciplined Use of Cash Extend AVONEX and RITUXAN through Lifecycle Management Accelerate TYSABRI Growth Advance our Pipeline SHAREHOLDER VALUE Key Levers to Maximize Shareholder Value
Slide 5: TYSABRI's Blockbuster Year
TYSABRI's Blockbuster Year 2003 2004 2005 2006 2007 FYE 2008 FYE 2009 TYSABRI U.S. Patients on Therapy 86 99 25 218 20100 24500 35 344 37600 48800 TYSABRI International Patients on Therapy 73 101 10 126 16900 23700 600 600 test +30% Patients on Therapy +30% 2003 2004 2005 2006 2007 FYE 2008 FYE 2009
Slide 6: Research to Reduce PML Risk and Improve Outcomes
Viral coat protein (VP1) variants Regulatory region JC Virus variants Research to Reduce PML Risk and Improve Outcomes 6 Management Prediction and Prevention Viral Factors Patient Factors Natalizumab Removal Stop Disease Progression JC Virus Antibody Test Prior Treatment With Immunosuppressants Nata
Slide 7: JC Virus Antibody Test
JC Virus Antibody Test 7 ELISA assay JC virus antibody detected in 50% to 60% of adults All TYSABRI-treated patients who developed PML, for whom samples were available prior to diagnosis (n=11), were anti-JCV antibody positive Additional evaluations are planned to define the potential utility of the
Slide 8: Driving Future TYSABRI Growth
Initiative Objective(s) Switching study vs. Copaxone(r) and Rebif(r) Reinforce efficacy Demonstrate benefit of switching early Demonstrate TYSABRI should be first choice switch therapy when you need more efficacy Geographic Expansion Expand market - increased footprint from 38 to 45 countries betwee
Slide 9: AVONEX Franchise Durability
AVONEX Franchise Durability 2009 2010+ Granted method of use patent through 2026 FPI Phase 3 PEGylated interferon trial CHAMPIONS 10-year results Completed Phase 2 enrollment in Ulcerative Colitis trial Autoinjector Titration Ulcerative Colitis Long term efficacy data Note: patent mentioned above is
Slide 10: Expanding the CD-20 Franchise
Expanding the CD-20 Franchise 2009 2010+ PRIMA NHL 1st line maintenance results FPI Phase I subcutaneous formulation trial RITUXAN RA label expanded to include new claim for improvement in physical function and guidance on retreatment for TNF-IR patients Next generation molecules: GA-101 in Oncology
Slide 11: 2010 Pipeline
Psoriasis Hemophilia B Rheumatoid Arthritis Crohn's Disease 2010 Pipeline Daclizumab Anti-LINGO AVONEX TYSABRI Ocrelizumab BG-12 BIIB014 Neublastin RITUXAN FUMADERM Pain Multiple Sclerosis Multiple Sclerosis Multiple Sclerosis Multiple Sclerosis Multiple Sclerosis Parkinson's MS Non-Hodgkin's Lympho